Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by BottomBrokeron Mar 03, 2021 11:31am
217 Views
Post# 32704958

Dr. Tanzi touts new AD drug

Dr. Tanzi touts new AD drughttps://www.studyfinds.org/alzheimers-pill-successful-test/

BOSTON — Although there’s no cure for Alzheimer’s disease yet, a new drug that could come in pill form is giving hope to millions of dementia patients around the world. Researchers say the potential Alzheimer’s drug prevents the disease in mice, rats, and monkeys during lab experiments.

The results are so “promising,” researchers expect clinical trials to begin in the next few months. Such a drug may also ward off the cognitive breakdown in genetically prone people who don’t have the condition yet. Study authors say vulnerable individuals would be able to get the medication after a simple blood test.

Targeting plaque buildups in the brain

A team from the University of California San Diego School of Medicine and Massachusetts General Hospital say the treatment belongs to a family of drugs called GSMs (gamma-secretase modulators). It works by destroying rogue proteins, beta-amyloid (Aβ), that form sticky clumps in the brain and destroy neurons.


The researchers are awaiting approval from the U.S. Food and Drug Administration for phase 1 studies to begin.“In this study, we have pharmacologically characterized a potent GSM that, based on its preclinical attributes, appears to equal or exceed the potency of any previously tested GSMs,” says lead co-author Dr. Rudolph Tanzi in a media release. “Future clinical trials will determine whether this promising GSM is safe in humans and could be used to effectively treat or prevent Alzheimer’s disease.”

“We hope to get started this year. It would be a typical single and multiple ascending dose in healthy individuals. If we are get through phase 1, phase 2A would be in Alzheimer’s patients and include looking at biomarkers for reducing beta-amyloid in the brain,” Dr. Tanzi adds in a statement to SWNS.

<< Previous
Bullboard Posts
Next >>